UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 17, 2018
Avinger, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-36817 |
|
20-8873453 |
(State or other jurisdiction of |
|
(Commission File Number) |
|
(IRS Employer |
400 Chesapeake Drive
Redwood City, California 94063
(Address of principal executive offices, including zip code)
(650) 241-7900
(Registrants telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Item 8.01. Other Events.
On January 17, 2018, Avinger, Inc. (the Company) received formal notification from The NASDAQ Stock Market LLC (Nasdaq) that the Nasdaq Hearings Panel (the Panel) had determined to grant the Companys request for the transfer of its listing from The Nasdaq Global Market to The Nasdaq Capital Market, pursuant to an extension through March 31, 2018 to evidence compliance with all applicable requirements for continued listing on Nasdaq. The Company is taking definitive steps to timely evidence compliance with the terms of the Panels decision; however, there can be no assurance that it will be able to do so.
As previously disclosed, on October 24, 2017 and November 21, 2017, the Company received written notice from the Nasdaq Listing Qualifications Staff (the Staff) indicating that, due to the Companys continued non-compliance with the $50 million market value of listed securities, $1.00 bid price and $15 million market value of publicly held shares requirements for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450, the Staff had determined to delist the Companys securities from The Nasdaq Global Market unless the Company timely requested a hearing before the Panel. The Panels decision, dated January 17, 2018, follows the Companys hearing before the Panel, at which it requested the transfer of its listing to The Nasdaq Capital Market pursuant to an extension through March 31, 2018 to evidence full compliance with all applicable requirements for the continued listing on Nasdaq, including the applicable $1.00 bid price and $2.5 million stockholders equity requirements.
On January 19, 2018, Avinger, Inc. issued a press release regarding the Nasdaq Listing Determination. A copy of this press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. |
|
Description |
|
|
|
99.1 |
|
FOR IMMEDIATE RELEASE
Avinger Granted Continued Listing Decision From Nasdaq
REDWOOD CITY, Calif., January 19, 2018 (GLOBE NEWSWIRE) Avinger, Inc. (NASDAQ: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that the Company has received formal notification that the Nasdaq Hearings Panel (the Panel) has granted the Companys request for the transfer of its listing from The Nasdaq Global Market to The Nasdaq Capital Market, pursuant to an extension through March 31, 2018 to evidence compliance with all applicable requirements for continued listing on Nasdaq, including the applicable $1.00 bid price and $2.5 million stockholders equity requirements. The Company is taking definitive steps to timely evidence compliance with the terms of the Panels decision; however, there can be no assurance that it will be able to do so. The Companys common stock will begin trading on The Nasdaq Capital Market effective with the open of business today, January 19, 2018.
Commenting on the Panels decision, Jeff Soinski, Avingers president and CEO, noted, Were pleased with the Panels decision and appreciate the additional time we now have to regain compliance with Nasdaqs listing standards. We are excited about the progress were continuing to make in the product development and commercial aspects of our business, and this decision by Nasdaq provides additional time for us to execute on our plans to materially improve the capitalization of the Company.
About Avinger, Inc.
Avinger is a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD). Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot family of chronic total occlusion (CTO) catheters, and the PantherisÒ family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding future compliance with Nasdaq listing requirements and the improvement of the Companys capitalization. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include our dependency on a limited number of products; our ability to demonstrate the benefits of our Lumivascular platform; the resource requirements related to Pantheris; the outcome of clinical trial results; potential exposure to third-party product liability, intellectual property and other litigation; lack of long-term data demonstrating the safety and efficacy of our Lumivascular platform products; experiences of high-volume users of our products may lead to better patient outcomes than those of physicians that are less proficient; reliance on third-party vendors; dependency on physician adoption; reliance on key personnel; and requirements to obtain regulatory approval to commercialize our products; as well as the other risks described in the section entitled Risk Factors and elsewhere in our quarterly Form 10-Q filing made with the Securities and Exchange Commission on November 14, 2017. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Avinger disclaims any obligation to update these forward-looking statements.
Public Relations Contact:
Phil Preuss
VP of Marketing & Business Operations
Avinger, Inc.
(650) 241-7900
pr@avinger.com
Investor Contact:
Matt Ferguson
Chief Business Officer & CFO
Avinger, Inc.
(650) 241-7917
ir@avinger.com
# # # #